Sunitinib maleate administration before percutaneous CT-guided cryoablation for large renal cell carcinoma: A case report

Nishizawa, Kaori; Katsumori, Tetsuya; Kotera, Yuya; Yoshikawa, Takahiro; Nishimura, Tomoaki

doi:10.1016/j.radcr.2022.09.047

Cited by 1 publication

(1 citation statement)

References 17 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There have been several reports on the efficacy of preoperative molecular-targeted drugs for T1b tumors in nephron-sparing surgery [3,4]. However, only one case report regarding local ablative therapy is available in the literature [5]. Here, we present six cases where the utilization of tyrosine kinase inhibitors (TKIs) prior to PCA resulted in tumor shrinkage and successful local control.…”

Section: Introductionmentioning

confidence: 92%

Preoperative Tyrosine Kinase Inhibitors Before Percutaneous Cryoablation for Clinical T1b Renal Tumors

Iwatani,

Kimura,

Urabe

et al. 2024

Cureus

View full text Add to dashboard Cite

To treat renal cell carcinoma, local ablative therapy is a viable alternative treatment option. Traditionally, cryoablation has been used for the treatment of T1a renal tumors. However, recent technological developments have expanded its application to encompass select T1b renal tumors. Here, we present a retrospective study of the utilization of preoperative tyrosine kinase inhibitors (TKIs) to induce tumor shrinkage and achieve favorable outcomes in percutaneous cryoablation (PCA). MethodsWe retrospectively evaluated the data from nine patients with clinical T1b renal tumors who underwent PCA. Six patients with TKI pretreatment at our institution between 2016 and 2018 were included in the study. We evaluated the safety and efficacy of preoperative TKIs prior to PCA. ResultsAll patients received axitinib with a median treatment duration of 80.5 days (IQR: 49-85). All patients experienced tumor shrinkage (median: 13.5 mm; IQR: 7-16); five experienced downstaging to T1a following tumor shrinkage. There were no severe adverse events (common terminology criteria for adverse events (CTCAE) grade ≥ 3) in TKIs. After the discontinuation of TKIs for two weeks, all PCA procedures were performed successfully without any severe complications. During a median follow-up of 46 months, no local recurrence was observed in any of these cases. ConclusionIn cases with large renal tumors, TKI pretreatment prior to PCA had potential benefits in terms of tumor shrinkage and long-term local control rate. Further well-designed studies in larger populations are needed to validate our findings.

show abstract

Section: Introductionmentioning

confidence: 92%